Dataset Information


Blockade of interferon-γ normalizes IFN regulated gene expression in subjects with systemic lupus erythematosus (SLE)

ABSTRACT: Normal donor blood was incubated with or without IFN-g stimulation to establish an IFN-g gene signature. Systemic lupus erythematosus subjects were treated with placebo or AMG 811, a therapeutic anti-IFN--g antibody, and changes in the IFN--g signature in whole blood of these subjects was measured. Blood from healthy volunteers (n=4) was collected into sodium heparin tubes, and then untreated or treated with 294 pM recombinant human IFN-γ for 0, 24, or 48 hours with incubation at 37oC, 5 % CO2. The blood was then added to PAXgene tubes and processed for RNA purification. Twenty six subjects with stable, mild to moderate SLE were administered placebo or a single dose of AMG 811 ranging from 2 mg to 180 mg SC or 60 mg IV. Whole blood PAXgene tube samples were collected from all cohorts at baseline, day-1 (pre-dose), and at days 15, 56, and end of study (EOS) after treatment Arrays were hybridized in a Loop design.

ORGANISM(S): Homo sapiens  

SUBMITTER: Mara Campbell   Panteha Kiaei 

PROVIDER: E-GEOD-78193 | ArrayExpress | 2016-02-24



altmetric image


Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus.

Welcher Andrew A AA   Boedigheimer Michael M   Kivitz Alan J AJ   Amoura Zahir Z   Buyon Jill J   Rudinskaya Alla A   Latinis Kevin K   Chiu Kit K   Oliner Kelly S KS   Damore Michael A MA   Arnold Gregory E GE   Sohn Winnie W   Chirmule Narendra N   Goyal Lovely L   Banfield Christopher C   Chung James B JB  

Arthritis & rheumatology (Hoboken, N.J.) 20151001 10

To assess the safety and immunologic impact of inhibiting interferon-γ (IFNγ) with AMG 811, a human IgG1 monoclonal antibody against IFNγ, in patients with systemic lupus erythematosus (SLE).Twenty-six patients with mild-to-moderate, stable SLE were administered placebo or a single dose of AMG 811, ranging from 2 mg to 180 mg subcutaneously or 60 mg intravenously.Similar to results previously reported following inhibition of type I IFNs, treatment of SLE patients with AMG 811 led to a dose-depen  ...[more]

Similar Datasets

2011-07-21 | E-GEOD-24757 | ArrayExpress
2013-09-01 | E-GEOD-46743 | ArrayExpress
2016-02-29 | E-GEOD-72754 | ArrayExpress
2011-11-10 | E-GEOD-19151 | ArrayExpress
2015-03-10 | E-GEOD-66573 | ArrayExpress
2015-06-22 | E-GEOD-65336 | ArrayExpress
2010-08-27 | E-GEOD-23848 | ArrayExpress
2011-09-01 | E-GEOD-24250 | ArrayExpress
2019-05-14 | E-GEOD-66573 | ExpressionAtlas
2009-05-17 | E-GEOD-16028 | ArrayExpress